We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 551

Expect the unexpected Patenting antibodies in Asia
  • FB Rice
  • China, Japan, South Korea
  • September 6 2016

Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to

Insight into recent PRB decisions on pharmaceutical biotech inventions
  • Peksung Intellectual Property Ltd
  • China
  • December 11 2015

The Patent Reexamination Board (hereinafter referred to as the PRB) is an organization under the SIPO (State Intellectual Property Office) of China

News and cases from China: August - September 2015
  • Rouse
  • China
  • October 29 2015

Recently, the National Copyright Administration issued Implementing Measures for the Copyright Administrative Penalties (Revision Draft for Comment

  • Beijing Sanyou Intellectual Property Agency Ltd
  • China
  • September 11 2015


Experimental use exemption of patent infringement ̶ a brief comparison of China and the United States
  • Peksung Intellectual Property Ltd
  • China, USA
  • February 3 2015

Generally, the purpose of a patent is to award the patentee a limited market monopoly for disclosing his invention to the public. Experimental use of

Patent protection for medical uses and relevant judicial practice in China
  • Wan Hui Da - Peksung IP Group
  • China
  • June 18 2014

The Supreme People's Court (hereinafter refers to as SPC) recently announced "2013 Top Ten Innovative Intellectual Property Cases of Chinese Court"

China’s Patent Re-Examination Board says pharmaceutical salts not patentable over pure compounds
  • Greenberg Traurig LLP
  • China
  • August 14 2013

In July 2013, the Patent Re-Examination Board of China's State Intellectual Property Office invalidated the U.S. biotech company, Gilead Sciences'

China newsletter - summer 2013
  • Greenberg Traurig LLP
  • China, Macau
  • July 17 2013

For the purpose of fully implementing the spirit of the Eighteenth National Congress of the Communist Party of China and attracting more foreign

Life sciences: 2013 legal developments you need to know about
  • Mayer Brown LLP
  • China, European Union, France, USA
  • July 16 2013

This is a short guide outlining some of the key legal developments in the life sciences sector in 2013. The developments include the Supreme Court

Changing trends in patent protection for the pharma industry
  • Heskia - Hacmun Law Firm
  • China, India, Israel
  • June 6 2013

This April India's Supreme Court oversaw a high profile case involving Novartis' patent application for Glivec, a cancer-battling medication